A Randomized, Double-blind, Placebo-controlled, 12-week Treatment Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs ACT 774312 (Primary)
- Indications Nasal polyps
- Focus Therapeutic Use
- Sponsors Idorsia Pharmaceuticals
- 04 Sep 2019 Planned End Date changed from 30 Sep 2019 to 30 Dec 2020.
- 04 Sep 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Nov 2020.
- 22 Oct 2018 Status changed from not yet recruiting to recruiting.